BidaskClub upgraded shares of Horizon Pharma (NASDAQ:HZNP) from a sell rating to a hold rating in a research report sent to investors on Saturday, March 3rd.
Several other research firms have also recently commented on HZNP. Cantor Fitzgerald set a $17.00 price target on Horizon Pharma and gave the company a buy rating in a report on Wednesday, December 27th. UBS Group set a $20.00 price target on Horizon Pharma and gave the company a buy rating in a report on Thursday, November 30th. Jefferies Group increased their target price on Horizon Pharma from $16.00 to $21.00 and gave the stock a buy rating in a report on Tuesday, November 7th. Piper Jaffray Companies reissued a buy rating and issued a $22.00 target price on shares of Horizon Pharma in a report on Thursday, March 1st. Finally, Cowen reissued a buy rating and issued a $24.00 target price on shares of Horizon Pharma in a report on Thursday, March 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $18.64.
Horizon Pharma (HZNP) opened at $15.59 on Friday. The company has a market capitalization of $2,588.69, a PE ratio of 13.44, a price-to-earnings-growth ratio of 0.67 and a beta of 1.34. Horizon Pharma has a 52 week low of $9.45 and a 52 week high of $16.02. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.63 and a quick ratio of 1.54.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. William Blair Investment Management LLC grew its holdings in shares of Horizon Pharma by 12.2% in the 4th quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock valued at $128,861,000 after acquiring an additional 958,414 shares in the last quarter. Sterling Capital Management LLC bought a new position in Horizon Pharma during the fourth quarter worth about $1,340,000. Segall Bryant & Hamill LLC grew its holdings in Horizon Pharma by 12.6% during the fourth quarter. Segall Bryant & Hamill LLC now owns 725,002 shares of the biopharmaceutical company’s stock worth $10,585,000 after purchasing an additional 81,074 shares during the period. Redmile Group LLC bought a new position in Horizon Pharma during the fourth quarter worth about $292,000. Finally, Cowen Inc. bought a new position in Horizon Pharma during the fourth quarter worth about $781,000. Institutional investors own 86.77% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/13/horizon-pharma-hznp-stock-rating-upgraded-by-bidaskclub/1965855.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.